IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 195 deferred shares on July 14, 2026, at $207.83 per share. Each deferred share is convertible into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, when he ceases to be a director, upon a change in control, or upon death, and there is no expiry date. Following this award, Fasano holds 6,268 deferred shares directly.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl received a grant of 160 deferred shares on 2026-07-14, representing rights to an equal number of common shares upon settlement. Under the Non-Employee Director Deferral Plan, these units settle when he leaves the board, upon a change in control, or upon death. Following the award, he holds 3,289 deferred shares directly.
IQVIA Holdings Inc. reported that its wholly owned subsidiary IQVIA Inc. issued €950,000,000 of 4.625% senior notes due 2033. These unsecured notes provide long-term euro-denominated funding. Interest is payable semi-annually on June 15 and December 15, beginning December 15, 2026.
The notes mature on June 15, 2033, unless earlier repurchased or redeemed under their terms. IQVIA plans to use the net proceeds to refinance certain existing indebtedness and to pay related fees and expenses, effectively replacing older debt with this new issue.
The notes were issued under an Indenture dated June 11, 2026, among IQVIA Inc. as issuer, U.S. Bank Trust Company, National Association as trustee, and certain subsidiaries as guarantors. The issuer may redeem the notes before maturity, including a make-whole premium before June 15, 2029, and thereafter at a redemption premium that declines from 2.313% to 0%.
IQVIA Holdings Inc. announced that its subsidiary, IQVIA Inc., has priced an offering of €950,000,000 in senior notes due 2033. The notes will bear interest at 4.625% per annum, paid semi-annually on June 15 and December 15, starting December 15, 2026, and will mature on June 15, 2033 unless earlier repurchased or redeemed. IQVIA plans to use the proceeds to refinance certain existing indebtedness and to pay fees and expenses related to the transaction. The issuance is expected to close on or about June 11, 2026, subject to customary closing conditions, and the notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., plans to raise €950,000,000 through an offering of senior notes due 2033. The company expects to use the proceeds to refinance certain existing indebtedness and to pay related fees and expenses.
The notes will not be registered under the Securities Act and will be offered privately to qualified institutional buyers in the United States under Rule 144A and to non-U.S. investors under Regulation S. Completing the offering is subject to market and other customary conditions and is not yet assured.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received an award of 171 deferred shares on May 7, 2026. The grant is recorded at a reference price of $178.64 per share and increases his directly held deferred share balance to 6,636 deferred shares.
Each deferred share is convertible into one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan. The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date on this award.
IQVIA Holdings Inc. director Colleen A. Goggins received a grant of 214 Deferred Shares on May 7, 2026, as part of her director compensation. Each deferred share is linked to one share of common stock and was valued at $178.64 per deferred share for reporting purposes.
After this grant, Goggins directly holds 5,114 Deferred Shares. These awards convert into common stock upon settlement and become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received an award of 228 deferred shares tied to the company’s common stock. The grant was priced at $178.64 per share and increased his directly held deferred share balance to 6,073.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, these deferred shares become settleable when Fasano ceases to be a director, upon a change in control of the company, or upon his death, and they have no expiry date.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl reported a grant of 185 deferred shares on May 7, 2026. These derivative securities were awarded at a reference price of $178.64 per deferred share and increase his directly held deferred share balance to 3,129.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. According to the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when Danhakl ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date.
IQVIA Holdings Inc. announced that its board of directors approved an additional $2 billion share repurchase authorization under its existing equity repurchase program, bringing the total remaining authorization to $3.2 billion. The program has no expiration date and does not require IQVIA to repurchase any specific amount of stock.
Repurchases may be made in open market transactions, block trades, or privately negotiated deals, and can be modified, extended, suspended or discontinued at any time based on IQVIA’s share price, corporate needs and overall market conditions.